Financial Highlights - Total Annual Recurring Revenue (ARR) reached $1043 million[8] - Subscription ARR grew by 30% year-over-year[8] - Subscription ARR constitutes 86% of the total ARR[8] - Non-GAAP Gross Margin is 80.5%[8] - SaaS Net Dollar Retention Rate (NRR) is 125%[8] - Non-GAAP EBIT Margin is 18.6%[8] Growth Metrics - SaaS ARR experienced a 56% year-over-year growth[9] - Total revenue increased by 18% year-over-year, reaching $276 million in Q2'26[47] - Subscription revenue increased by 29% year-over-year, reaching $173 million in Q2'26[49] Market and Customer Base - The company estimates a $24 billion Total Addressable Market (TAM) across Data Security, Cloud Security, and Core Data Protection[10] - The company has over 13,000 subscription customers[8, 11]

Q3 2025 Performance Highlights - Backlog reached a record level of $720 million, a 64% increase year-over-year[13, 20] - Orders increased by 44% year-over-year to $233 million, resulting in a book-to-bill ratio of approximately 1.2x[12, 13] - Revenue grew by 46% year-over-year to $198 million, driven by market position, M&A, and growth investments[12, 13] - Adjusted EBITDA increased by 62% year-over-year to $23.2 million, with margin expansion of 120 bps[12, 13, 20] - Adjusted EPS increased by 86% year-over-year to $0.26[13, 20] Full Year 2025 Outlook (Reaffirmed) - Revenue is projected to be between $725 million and $775 million, representing approximately 35% year-over-year growth, with 20% organic growth[15] - Adjusted EBITDA is expected to be between $90 million and $100 million, up approximately 50% year-over-year, with margins in the range of 12.5% - 13.0%[12, 15] - Expect Q4 bookings to be greater than $250 million[15] 2026 Outlook (Introducing) - Revenue is projected to be between $850 million and $950 million, representing a 15% to 25% year-over-year increase[10, 36, 38] - Orders are expected to exceed $1 billion[10, 36, 38] - Adjusted EBITDA is projected to be between $110 million and $130 million, representing a 20% to 40% year-over-year increase[10, 36, 38]

Financial Performance - GeneDx grew revenues to $116.7 million, a 52% increase year-over-year[4] - Exome and genome test revenue grew to $98.9 million, a 65% increase year-over-year[4] - The company delivered an adjusted gross margin of 74%, up from 64% in the third quarter of 2024[4] - Adjusted net income was $14.7 million in the third quarter of 2025[4] - Cash, cash equivalents, marketable securities, and restricted cash were $156.1 million as of September 30, 2025[13] Business Highlights - The company's exome and genome volume grew 33% year-over-year[10] - Exome and genome tests accounted for 43% of all tests reported[10] - GeneDx received FDA Breakthrough Device Designation for the GeneDx ExomeDx and GenomeDx[6] Strategic Initiatives and Market Expansion - GeneDx is participating in the NIH's BEACONS Initiative and Florida's Sunshine Genetics Network for genomic newborn screening[6] - The company is strategically investing to accelerate long-term growth drivers, with Q3 2025 adjusted total operating expenses of $71 million[14, 17] - Medicaid programs are expanding access to exome and genome sequencing, with 36 states covering exome or genome testing and 17 states covering rapid genome sequencing[63] Guidance - The company updated its full-year 2025 revenue guidance to $425 to $428 million[18] - The company expects growth in exome and genome revenue of 53% to 55%[18]

2025 Third Quarter Financial Results Roei Golan CFO October 28, 2025 Kip E. Meintzer Global Head of IR ©2025 Check Point Software Technologies Ltd. 1 Nadav Zafrir CEO Forward Looking Statement Q3-25 Revenues & EPS This presentation may contain certain forward-looking statements. These forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements in this report include, but are not limited to: Non-GAAP** Our expectations regarding ou ...

Third Quarter Earnings Presentation October 28, 2025 Important Notices and Disclaimers Forward-Looking Statements This presentation contains "forward-looking statements" including statements with respect to the Company's objectives, expectations and intentions and other statements that are not historical facts. Examples of forward- looking statements include but are not limited to: our future operating or financial performance, including revenues, expenses, expense savings, income or loss and earnings or lo ...

Financial Performance - Clinical revenue increased by 18%[17], or 15% excluding Pathline[20] - Clinical volume grew by 15%[19], or 10% excluding Pathline[20] - NGS revenue increased by 24% year-over-year[20] - Adjusted gross profit was $85 million, a 7% increase from the prior year[19, 20] - Adjusted EBITDA was $12 million, representing a 9% decrease[19] Financial Overview (Q3 2025 vs Q3 2024) - Revenue increased by 11.9% to $187.8 million[22] from $167.8 million[22] - Adjusted gross profit increased by 6.6% to $85.4 million[22] from $80.1 million[22] - Adjusted gross margin decreased by 228 bps to 45.5%[22] from 47.8%[22] - Adjusted EBITDA decreased by 8.5% to $12.2 million[22] from $13.4 million[22] - Cash and cash equivalents decreased by 54.7% to $164.1 million[22] from $361.9 million[22] FY 2025 Guidance - Revenue is projected to be between $720 million and $726 million, representing a year-over-year growth of 9% to 10%[21] - Adjusted EBITDA is projected to be between $41 million and $44 million, representing a year-over-year growth of 3% to 10%[21]

Q3 2025 EARNINGS October 28, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements are statements other than historical fact that provide current expectations or forecasts of future events based on certain assumptions and are not guarantees of future performance. Forward-looking statements use words such as "anticipate," "believe," "continue," "could," "designed," "effect," "estimate," "evaluate," ...

Financial Performance - Earnings per share were $0.09[7] - Operating Funds From Operations (OFFO) per share were $0.28[10] - Year-to-date (YTD) Same-Property Net Operating Income (SPNOI) growth was +3.7%[11] - The company revised its 2025 net income attributable to Curbline guidance to $0.35-$0.38 per share and OFFO guidance to $1.04-$1.05 per share[33] Leasing Activity - Straight-line new leasing spreads were +40% in 3Q25[6, 16] - Straight-line renewal spreads were +21% in 3Q25[6, 16] - Blended straight-line lease spread for 3Q25 was +27.4%[12] - Leased rate increased to 96.7%, up 60 basis points sequentially[6, 16] Acquisitions and Investments - Acquired 37 properties in 3Q25 for $336 million[6, 12] - Year-to-date acquisitions totaled 69 properties for $644 million, including 2 properties for $29 million in 4Q25 to date[6] Liquidity and Capital - The company had over $800 million of liquidity as of September 30, 2025, including $430 million in cash and $400 million of credit facility availability[6, 27] - $300 million of debt capital was funded in 3Q25, including a $150 million term loan and a $150 million private placement[6] - Priced a $200 million private placement transaction in October 2025, expected to be funded around year-end 2025[6, 28]

Financial Performance & Growth Strategy - NXP aims for high single-digit organic revenue growth and gross margin expansion above 60%[10, 124] - The company plans to return 100% of excess free cash flow (FCF) to its owners[10, 124] - NXP targets doubling non-GAAP EPS by 2030+[11, 125] - NXP's revenue is projected to grow from $12.6 billion in 2024 to approximately $16.0 billion in 2027, with a CAGR of 6-10%[36] Market Positioning & Opportunities - Automotive and Industrial & IoT sectors are expected to drive growth at the intelligent edge, within a $1.3 trillion semiconductor market opportunity[16, 17] - Automotive revenue is expected to grow at a CAGR of 8-12% from 2024 to 2027, reaching ~$9.5 billion[42, 51] - Industrial & IoT revenue is projected to increase at a CAGR of 8-12% from 2024 to 2027, reaching ~$3.1 billion[48, 51] Financial Results (Q3 2025) - Q3 2025 revenue was $3.173 billion, an increase of 8% quarter-over-quarter but a decrease of 2% year-over-year[75] - Non-GAAP gross profit for Q3 2025 was $1.810 billion, resulting in a gross margin of 57.0%[78, 117] - Non-GAAP operating profit for Q3 2025 was $1.071 billion, yielding an operating margin of 33.8%[78, 117] Capital Return & Debt - NXP's cumulative capital return from 2018 to 2024 was $19.2 billion, representing 109% of non-GAAP FCF[91] - The company's net debt stood at $8.281 billion as of Q3 2025, with a net leverage of 1.8x[94]

PayPal Third Quarter 2025 Performance Financial results & company highlights October 28, 2025 Non-GAAP Financial Measures This presentation contains non-GAAP measures relating to our performance. These measures may exclude certain expenses, gains and losses that may not be indicative of our core operating results and business outlook, and, in each case, may be different from the non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under a ...